HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer

Da Silva, Leonard; Simpson, Peter T; Smart, Chanel E; Cocciardi, Sibylle; Waddell, Nic; Lane, Annette; Morrison, Brian J; Vargas, Ana Cristina; Healey, Sue; Beesley, Jonathan; Pakkiri, Pria; Parry, Suzanne; Kurniawan, Nyoman; Reid, Lynne; Keith, Patricia; Faria, Paulo; Pereira, Emilio; Skalova, Alena; Bilous, Michael; Balleine, Rosemary L; Do, Hongdo; Dobrovic, Alexander; Fox, Stephen; Franco, Marcello; Reynolds, Brent; Khanna, Kum Kum; Cummings, Margaret; Chenevix-Trench, Georgia; Lakhani, Sunil R

doi:10.1186/bcr2603

Breast Cancer Research

Table 1 Somatic mutations identified by OncoCarta and ER, PgR and HER family of receptors assessment

From: HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer

Matched breast primary-brain metastasis pairs
Case ID#	Site	ER - PgR- HER 1-2-3-4	EGFR		NRAS		PIK3CA
			Mutation	MAP	Mutation	MAP	Mutation	MAP
1	brain	ER-, PgR-, HER1-, HER2+, HER3-, HER4-
	breast	ER-, PgR-, HER1-, HER2+, HER3-, HER4-
2	brain	ER-, PgR-, HER1-, HER2-, HER3+, HER4-			Q61R^{O, H, I, S}	39.50%
	breast	ER-, PgR-, HER1-, HER2-, HER3+, HER4-			Q61R^{O, H, I, S}	38.30%
4	brain	ER-, PgR+, HER1+, HER2-, HER3-, HER4-
	breast	ER-, PgR+, HER1+, HER2-, HER3-, HER4-
6	brain	ER-, PgR+, HER1+, HER2-, HER3-, HER4-
	breast	ER-, PgR+, HER1+, HER2-, HER3-, HER4-
7	brain	ER-, PgR-, HER1+, HER2-, HER3-, HER4-			Q61R^{I, S}	34.4%
	breast	ER-, PgR-, HER1+, HER2-, HER3-, HER4-			Q61R^{I, S}	34.1%
8	brain	ER-, PgR-, HER1-, HER2+, HER3+, HER4-
	breast	ER-, PgR-, HER1-, HER2+, HER3-, HER4-
9	brain	ER-, PgR-, HER1-, HER2+, HER3-, HER4-					H1047R^S	79.50%
	breast	ER-, PgR-, HER1-, HER2+, HER3-, HER4-					H1047R^S	79.50%
10	brain	ER-, PgR-, HER1+, HER2-, HER3+, HER4-					E545K^{H, NVP}	23.40%
	breast	ER-, PgR-, HER1+, HER2-, HER3-, HER4-					E545K^{H, NVP}	18.20%
11	brain	ER-, PgR-, HER1-, HER2+, HER3-, HER4+
	breast	ER-, PgR-, HER1-, HER2+, HER3-, HER4+
12	brain	ER-, PgR+, HER1-, HER2-, HER3+, HER4-
	breast	ER-, PgR+, HER1-, HER2-, HER3+, HER4-
13	brain	ER-, PgR-, HER1+, HER2-, HER3-, HER4-
	breast	ER-, PgR-, HER1+, HER2-, HER3-, HER4-	N771_P772>SVDNR	12.10%
14	brain	ER-, PgR-, HER1+, HER2-, HER3-, HER4-
	breast	ER-, PgR-, HER1+, HER2-, HER3-, HER4-
Unmatched brain metastases from primary lung, colon, melanoma and kidney tumours
Case ID#	Site	ER - PgR- HER 1-2-3-4	*EGFR*		*HRAS*		*KRAS*		*NRAS*		*PIK3CA*
			Mutation	MAP	Mutation	MAP	Mutation	MAP	Mutation	MAP	Mutation	MAP
D2	melanoma	n.a.									E545K^{H, I, Y}	30.80%
D3	colon	n.a.					G12C^S	38.90%
D4	lung	n.a.	E746_A750del^A	21.00%
D5	lung	n.a.
D6	lung	n.a.	E746_A750del^{A, NVI}	14.40%	G13S^I	17.30%			G12C^I;S	35.70%
D7	lung	n.a.							G12C^O;I	9.70%
D8	lung	n.a.					G12C^S	39.90%
D9	lung	n.a.									E545K^H	13.30%
D10	kidney	n.a.	E746_A750del^{A, I}	9.10%					G12C^{I, S}	35.20%

A, validated by immunohistochemistry using a mutation-specific antibody; ER, estrogen receptor; H, validated by High Resolution Melt analysis; I, validated by iPLEX; ID, case number identification; MAP, Mutant Allele Proportion estimated by OncoCarta; NVI, not validated by iPLEX; NVP, no further validation possible because no DNA remained; O, validated by repeat OncoCarta; PgR, progesterone receptor; S, validated by sequencing; Y, sequencing did not work for this sample; n.a., not accessed.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com